Il nuovo paradigma della medicina personalizzata e di precisione per una più ampia misura di prevenzione atta a migliorare la salute delle donne: prevenzione delle malattie versus cura
Maria Luigia Pallotta, Dept Medicine and Health Sciences, Molise University Europe pallottamarialuigia@gmail.com
Foto Maria Teresa Pallotta
Una new age per la terapia dei tumori è stata inaugurata al fine di assistere la comunità medico/scientifica in un nuovo approccio alla Medicina 4P (Personalizzata, Predittiva, Preventiva e Partecipativa)[1-3]. Con la rapida evoluzione della tecnologia, l’Intelligenza Artificiale è divenuta uno strumento fondamentale e sta rapidamente rimodellando la medicina di precisione incorporando dati clinici e sanitari standard assieme ad una “panomica” avanzata [i.e.(trascritt/epigen/prote/metabol/microbi]omica) per una profonda fenotipizzazione [4]. Queste applicazioni spaziano dal rilevamento alla caratterizzazione molecolare della lesione tumorale, dal microambiente, alla ricerca di farmaci atti a prevedere i potenziali risultati dei trattamenti sui pazienti [5]. Outcome favorevoli sono stati ottenuti attraverso una crescente comprensione della biologia alla base del cancro, l’emergere di strumenti innovativi per l’identificazione e il rilevamento di precisi biomarcatori predittivi. I ricercatori stanno ora esplorando approcci di precisione in ambiti diversi dall’oncologia, tra cui neuroscienze, immunologia e la medicina di genere. I fattori connessi allo stile di vita, come la dieta e l’esercizio fisico, saranno incorporati nei piani di intervento al fine di focalizzarsi su una misura preventiva più ampia volta a migliorare in toto il benessere delle donne. Inoltre, una politica e una agenda economica ad hoc saranno necessarie al fine di adottare questo nuovo paradigma nell’assistenza sanitaria. Nel simposio “Precision Medicine and Functional Genomics 2021”, le relatrici costituivano il 35% dei delegati così evidenziando il ruolo vitale espresso dalle donne [7] nella diagnostica medica più innovativa. Referenze 1]Pallotta ML 2015 The Aquarian Age in cancer therapy: biobankers, biomarkers, and much more
getting of the root of the problem NAD+an ancient metabolite with surprising modernity Mitochondrial NAD pool, tumour microenvironment and metastasis Cell Symposia, Multifaceted Mitochondria, Chicago 2]Pallotta ML 2015 Boosting NAD(P)+biosynthesis with NAD(P)+intermediates and monitoring mitochondrial NAD(P)+/NAD(P)H pool by means of Fluorescence-Based techniques could be a strategy for preventing and treating Woman’s Cancers. FEBS Berlin 3]Pallotta ML 2016 Monitoring NAD(P)H levels and their relevance to bioenergetics using Fluorescence-Based Strategies in salivary samples: a possible biomarker in the detection of cancer and precancer EUSTM on New Horizons in Translational
Maria Luigia Pallotta, Bio[chemist/physicist], Royal Society Medicine Fellow, American Association for Advancement of the Sciences Membership,Member of Senate of University of Molise 1999/2003,Membership SIB (Italian Sociaty of Biochemistry) and GIBB (Italian Group of Bioenergetics and Biomembranes) since 1999, European Society for Translational Medicine, International Society of Microbiota 2016, European Society of Clinical Investigation and Società Italiana di Biochimica Clinica e Biologia Molecolare chimica (2019) Member of the council of PhD in Applied Biochemistry and Chemistry (from 2003 to 2005) & Health Science, University of Molise (from 2005 to 2014) Bentham Science Ambassator, Coordinatore 500 giovani donne scienziate (un gruppo “no profit” dedicato a rendere la scienza aperta, inclusiva e accessibile., POD Campobasso (Molise, EUROPE) and More that meets the eye see http://docenti.unimol.it/index.php?u=pallotta
The new personalised and precision medicine paradigm for a wider preventative measure to improve women’s health: disease prevention versus treatment
A new age for cancer therapy has been inaugurated for assisting the medical community in a novel approach on 4P Medicine (viz Personalized, Predictive, Preventive and Partecipatory)[1-3]. Artificial intelligence (AI) is rapidly reshaping cancer research and personalized clinical care. Availability of high-dimensionality datasets coupled with advances in high-performance computing, as well as innovative deep learning architectures, has led to an explosion of AI use in various aspects of oncology research. These applications range from detection and classification of cancer, to molecular characterization of tumors and their microenvironment, to drug discovery and repurposing, to predicting treatment outcomes for patients. Favorable outcome has been driven by a growing understanding of the underlying biology of cancer, the emergence of innovative tools and technologies for biomarker identification and detection. Researchers are now exploring precision approaches in different fields of medicine, including neuroscience, immunology and women’s health. Precision medicine incorporates standard clinical and health record data with advanced panomics [ie, (transcript/epigen/prote/metabol/micro)biomics) for deep phenotyping. Lifestyle factors, such as diet and exercise, will be incorporated into personalised and precision medicine (PPM) treatment plans and will become the focus for a wider preventative measure to improve women’s wellbeing. Moreover, a policy and economic agenda will be necessary for the adoption of this new paradigm of health care globally.Recently, 35% of the presenters at the Precision Medicine and Functional Genomics 2021 Symposium were female Their remarkable work served as a powerful reminder of the vital role women play in the field of science